Financial PerformanceTempus achieved $1 billion of revenue faster than any other precision oncology lab company, showcasing its capital-efficient business model.
Revenue GrowthAmbry's $63M revenue beat expectations with approximately 23% underlying growth driven by strong unit volume growth in hereditary testing.
Strategic PartnershipsTempus announced an agreement worth $200mm with AstraZeneca and Pathos AI to develop the largest multimodal foundation model in oncology, representing a first of its kind partnership type for Tempus.